Rayonier Advanced Materials walks into its Q1 2026 print today with one striking contradiction: a near-perfect history of beating analyst estimates, and a stock that has fallen 13% in the past month to $9.29.
The most telling setup signal is in the options market — though not in an alarming way. The put/call ratio is running at 1.23, close to its 20-day average of 1.20, with a z-score barely above zero. That reads as neither fearful nor complacent. Notably, the PCR has cooled from a more defensive peak near 1.59 in late April, suggesting investors have been trimming downside hedges as the print approaches. Borrow conditions add little drama: cost to borrow is a negligible 0.51%, and availability is wide — the lending pool is nowhere near stressed. Short interest at 4.5% of the free float has risen 22% over the past month in share terms, but remains modest in absolute size and the borrow market shows no sign of friction.
The bull case rests heavily on RYAM's earnings execution record. The company ranks in the 93rd percentile universe-wide on EPS surprise — a track record that is genuinely exceptional for a specialty chemicals name of this size. Bulls point to rising Canadian volumes, an upgraded Paperboard segment guidance of $25 million for 2025, USMCA tariff compliance, and a weaker dollar contributing an estimated $10 million tailwind. The two most recent confirmed earnings events — in early March 2026 — produced one-day moves of +8.6% and +14.2% respectively, with five-day follow-through of +20% and +14%. That history speaks to a market willing to re-rate sharply on positive surprises.
Bears are focused on structural headwinds that beat history cannot paper over. The High-Yield Pulp segment reported Adjusted EBITDA of negative $6 million, missing even the negative $4.8 million forecast. Management flagged accelerating acetate destocking, second-order tariff volume impacts, and an expected oversupply in Chinese markets as pressures likely to persist into 2025 and beyond. RBC Capital — the sole covering analyst — maintained its Outperform rating after the last print and raised its target sharply from $9 to $14, but that action was in early March; the stock has since given back much of the post-earnings pop. The current price of $9.29 against RBC's $14 target implies meaningful upside on the bull thesis, but the gap also reflects how much execution uncertainty the market is pricing in.
The print is therefore less about whether RYAM can beat a headline number and more about whether management's pulp segment narrative has stabilised — and whether the acetate destocking cycle is closer to a floor or still deepening.
See the live data behind this article on ORTEX.
Open RYAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
